1931 ・ The late Dr. Kiichiro Hasumi advanced the hypothesis of cancer propagation by virus and started studies to prove his theory. 1946 ・ Electro-Chemical & Cancer Research Institute was founded in Chofu-City, Tokyo, Japan. 1948 ・ Clinical application of the Hasumi Vaccine was started. 1958 ・ Shukokai Incorporated was established and the Shukokai Clinic & Office opened. 1961 ・ An experiment to prevent cancer generation by applying the Hasumi Vaccine was started in Heguri-mura Village, Nara Prefecture, Japan. 1988 ・ Dr. Kenichiro Hasumi was appointed chairman of Shukokai Incorporated. 1990 ・ Hijirigaoka Hospital was opened. ・ LAK therapy was started. 1991 ・ The first research reports offered by the Electro-Chemical & Cancer Research Institute were published and have continued to be published on an annual basis, each year since. 1995 ・ Basic and applied research studies taking advantage of Dendritic cells was started. 1996 ・ A hospice was opened at the Hijirigaoka Hospital, making the hospital the fourth relief care facility in Tokyo, Japan. ・ The Immunotherapy Conference was started. 1997 ・ The present chairman, Dr. Kenichiro Hasumi was appointed visiting professor at Thomas Jefferson University. ・ The Hasumi Laboratory was opened at the university and the research and development of immunotherapy was started. 1998 ・ Joint research with the Jilin Provincial Cancer Hospital located in Jilin Province of China was started. ・ Dr. Kenichiro Hasumi was appointed chairman emeritus of the hospital. 1999 ・ The Hijiri-no-Sato Elderly Health Care Facility was opened. ・ Dr. K. Hasumi Fund was established in the US, to facilitate cancer research. ・ Shukokai International was established in the US, to promote overseas research of the Hasumi Vaccine. ・ Paraguay certified the Hasumi Vaccine for the first time. ・ The FIOCRUZ Research Institute of the Health Department of Brazil and Fortaleze Claude Bernard Research Institute (Brazil) started clinical research of the Hasumi Vaccine. ・ SIJ Co., Ltd. was established and its cooperation with Shukokai International (USA) was started. 2000 ・ Management of Shukokai group was improved by introducing GMP. GLP. ・ Self-entry medical records were introduced at Shukokai Clinic & Office. The importance of self-management of disease was stressed. 2001 ・ Tokyo Metropolitan Government certified the NPO Immunotherapy Conference. ・ In cooperation with Saitama Medical School and Changchun College of Traditional Chinese Medicine, the Electro-Chemical & Cancer Research Institute developed the Immuno Hasumi, an anti-cancer Chinese traditional medicine, and started its clinical application. ・ In joint research with Thomas Jefferson University, the Hasumi DC & AT Vaccine was developed and its clinical application was started. ・ The first symposium entitled, "The Recognition and Elimination Mechanism of Cancer" with Hiroyuki Itsuki, a popular novelist, as its keynote speaker, was held in Osaka under the auspices of NPO Immunotherapy Conference. ・ The clinical trial on Hasumi Vaccine was started in Brazil. "International Cancer Vaccine Symposium" was held in Tokyo under the auspices of Dr. K. Hasumi Fund, successfully attracting many famous scholars who are conducting cancer research internationally. 2002 ・ The R&D project on immno-supplements was launched and collaborated with Shukokai International, USA. ・ Dr. Kenichiro Hasumi was invited as a keynote speaker for the cancer vaccine section to the 10th International conference "AIDS, Cancer and Related Problems" held in St. Petersburg, Russia. ・ Sponsored the 2nd NPO Immunotherapy Conference "Living at Present by Understanding its Past" held in Tokyo, with Madam Keiko Kishi (actress) as the guest speaker ・ Sponsored Hasumi International Research Foundation, USA (Hasumi Foundation) to start preparing a clinical trial for cancer vaccine in Mexico ・ Sponsored Hasumi Foundation to develop an advanced testing method "CTL Elispot Assay" and implemented it to analyze the effect of immune response for Hasumi Vaccine treatment ・ Sponsored Hasumi Foundation to publish a most comprehensive book on cancer vaccine "Zeroing In On the Cancer Cell" to globally enlighten and increase awareness of cancer vaccine. ・ Opened "Cell Therapy Center" to provide cells which are totally safe with our stable technology which is proven in years of results. 2003 ・ Sponsored Hasumi Foundation to organize "International Cancer Vaccine Symposium" held in Beijing, collaborated with the National Cancer Institute, Chinese Academy of Medical Sciences. ・ Founded "Shukokai Pharmaceutical R&D in Beijing" and started working in cooperation with Beijing University of Chinese Medicine. ・ Sponsored the 3nd NPO Immunotherapy Conference "Freeing from Cancer" held in Kyoto, with Mr. Akira Takashi (writer) as the guest speaker. 2004 ・ Developed and implemented a new vaccine "Super Marignase" to boost immune response ・ Founding a nonprofit organization "Hasumi Vaccine Users Association" to support the Hasumi Vaccine users ・ Sponsored the Late Dr. Kiichiro Hasumi's Centennial Birth Anniversary" organized by "Sei-Ren-Kai" (one of the major Hasumi Vaccine uses associations) ・ Sponsored Hasumi Foundation to organize "International Cancer Vaccine Symposium" held in London, collaborated with the Royal Society of Medicine, United Kingdom ・ Incorporated "IMUH" to advance the development of unique immunological testing methods for cancer immunotherapies and their diffusions as a part of effective modalities in new cancer treatment ・ Developed and implemented a new vaccine "β-VACS" to boost immune response ・ Introduced CT Scan to the Tokyo Clinic to provide advanced treatment to the patients 2005 ・ Developed and implemented a new vaccine "HITV" for the advanced stage patients ・ Opened "Shanghai Office" to prepare for the Chinese market ・ Hijirigaoka Hospital was recognized and certified as a Quality Health Care Facility by Japan Council for Quality Health Care. 2003 Shukokai Inc.